Martinsried/Munich, Germany, December 22, 2009. The Supervisory Board of MediGene AG (Frankfurt: MDG, Prime Standard, TecDAX) has decided to nominate Dr. Thomas Werner for election to the Supervisory Board at MediGene AG's next annual shareholders' meeting. The Company will apply for the court appointment of Dr. Werner to the currently vacant position in the Supervisory Board until the next annual shareholders' meeting takes place.
Dr. Werner has over 25 years of experience in the pharmaceutical industry, and served as the CEO of GlaxoWellcome Germany and GlaxoSmithKline Germany from 1997 to 2008. Prior to that, between 1990 and 1997, he held a variety of managerial positions within the pharmaceutical group Bristol-Myers Squibb. Since the beginning of 2009, he has served as a venture partner in the internationally-active VC company Venture Partner Inventages. Dr. Werner additionally serves as a member of the Board of Trustees for the Paul-Ehrlich Institute and is also a member of other international boards.
Prof. Dr. Ernst-Ludwig Winnacker, Chairman of MediGene AG's Supervisory Board, commented, "We are very pleased to be able to nominate Dr. Thomas Werner as a candidate for Supervisory Board member of MediGene AG. MediGene will greatly benefit from his stellar knowledge and contacts in the pharmaceutical and biotechnology sector as the company pursues its business objectives."
This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademark of MediGene AG. These trademark may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt: MDG, Prime Standard, TecDax) biotechnology company located in Martinsried/Munich, Germany, Oxford, UK, and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are distributed by partner companies. MediGene has several drug candidates in clinical development, two of which provide significant sales potential. In addition, the company pursues several development projects and possesses innovative platform technologies for drug development. MediGene concentrates on clinical research and development of novel drugs with the focus on oncology.
Contact MediGene AG
Fax:++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 – 2946